How Do You Know If A REMS Is Effective? Look At Postmarket Data, Surveys, Patient Access
Executive Summary
US FDA draft guidance describes how to determine if a Risk Evaluation and Mitigation Strategy is meeting its goals; another guidance advises how to conduct REMS knowledge surveys.
You may also be interested in...
Drug Safety: FDA Pushes To Publicly Release REMS Assessments, Says It Will Improve Plan Design
Proposal would allow stakeholders to see data on REMS goals like provider training and the US FDA’s conclusions about their effectiveness.
Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients
US FDA will take multiple factors into account when deciding whether single shared-system REMS requirement is necessary.
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.